Conflicting Perspectives on the Value of Neprilysin Inhibition in Heart Failure Revealed During Development of a Decision Aid Focusing on Patient Costs for Sacubitril/Valsartan
Circulation: Cardiovascular Quality and Outcomes, <a href=”https://www.ahajournals.org/toc/circoutcomes/13/9″>Volume 13, Issue 9</a>, September 1, 2020.